21-hydroxylase deficiency overview: Difference between revisions
(Created page with "__NOTOC__ {{Congenital adrenal hyperplasia due to 21-hydroxylase deficiency}} {{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}} ==Overview== '''Congenital adrenal hyperp...") |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Congenital adrenal hyperplasia due to | {{Congenital adrenal hyperplasia due to 21-hydroxylase deficiency}} | ||
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}} | {{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}} | ||
Revision as of 15:15, 20 September 2012
|
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency Microchapters |
|
Differentiating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
21-hydroxylase deficiency overview On the Web |
|
American Roentgen Ray Society Images of 21-hydroxylase deficiency overview |
|
Directions to Hospitals Treating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |
|
Risk calculators and risk factors for 21-hydroxylase deficiency overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OH CAH), in all its forms, accounts for about 95% of diagnosed cases of congenital adrenal hyperplasia, and "CAH" in most contexts refers to 21-hydroxylase deficiency.